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INTRODUCTION
Clinically, breast cancer develops through sequential stages 
from normal ductal epithelium to hyperplasia, ductal carcino-
ma in situ (DCIS), invasive cancer, and metastatic carcinoma. 
Although extensive research has focused on identifying the 
molecular changes involved in carcinogenesis, the mechanisms 
underlying the development of breast cancer remain unclear 
[1]. Various reports have demonstrated that the expression of 
Annexin A1 (ANXA1) is ordinarily regulated in the mammary 
gland during the developmental period. Although the molecular 
action of ANXA1 is not yet fully understood, ANXA1 appears 
to take part in intracellular signaling and cell differentiation. 
ANXA1 is a 37-kDa calcium- and phospholipid-binding pro-
tein of the annexin superfamily, and has been detected in mis-
cellaneous organisms, including vertebrates, invertebrates, and 
plants [2]. Further, ANXA1 is an important mediator in glu-
cocorticoid-regulated inflammatory responses that modulates 
the activation of innate immune cells, such as neutrophils and 
macrophages [3], and it is known to have an association with 
dexamethasone-induced cell growth arrest [4]. The ANXA1 
protein is partially located in the nucleus of endothelial cells, 
which indicates that it has a role in an intracellular signaling 
pathway. Because ANXA1 is distinctively expressed in the 
mammary gland during embryonic development [5-7], we 
postulate an association between ANXA1 and breast cancer 
development. Decreased expression of ANXA1 has been con-
sistently reported at both the RNA and protein levels in breast 
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Purpose: The expression of Annexin A1 (ANXA1) is known to be 
reduced in human breast cancer; however, the role of ANXA1 
expression in the development of breast cancer remains unclear. 
In this study, we determined the relationship between the expres-
sion features of ANXA1 and the prognostic factors of breast can-
cer. Methods: Human breast tissues were obtained from patients 
specimens who had undergone breast surgery or core needle 
biopsies. The patterns of ANXA1 expression were analyzed by 
immunohistochemical staining in relation to histopathological   
diagnosis, clinical characteristics and outcomes. Results: One 
hundred eighty-two cases were included and the mean age of 
the patients was 46.34 ± 11.5 years. A significant loss of ANXA1 
expression was noted in both ductal carcinoma in situ (DCIS) and 
invasive carcinomas compared to normal breast tissues (p<0.001) 
and benign breast diseases (p<0.001). There was a significant 
alteration in ANXA1 expression according to hormone receptor 
status (p<0.001), cancer intrinsic type (p<0.001), and nuclear 
grade (p=0.004) in invasive cancer. In a univariate analysis, ANXA1 
positivity tended to be related with poor breast cancer-related sur-
vival (p=0.062); however, the same results was not realized in 
multivariate results (p=0.406). HER2 overexpression and TNM 
staging were significantly associated with relapse-free survivals 
(RFS) in the multivariate analysis (p=0.037, p=0.048, respectively). 
In particular, in node-positive patients (p=0.048), HER2 over- 
expressed patients (p=0.013), and non-triple negative breast can-
cer patients (p=0.002), ANXA1 overexpression was correlated 
with poor RFS. Conclusion: Although significant loss of ANXA1 
expression was noted in breast cancer including DCIS and inva-
sive carcinoma, in cases of invasive cancer, overexpression of 
ANXA1 was related to unfavorable prognostic factors. And these 
results imply that ANXA1 plays dualistic roles and is involved in 
variable mechanisms related to cancer development and pro-
gression.
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cancer [8,9]; however, the role of ANXA1 expression in tumor 
initiation or progression has remained unclear. In this study, we 
specified the patterns of ANXA1 expression in various breast 
diseases including benign tumors and malignancies and then 
analyzed the relationship with prognostic factors and survivals 
of ANXA1 in invasive breast cancer.
METHODS
Patients
Between April 2005 and December 2007, human breast tissue 
samples from benign or malignant lesions were retrieved from 
patients who had undergone breast surgery or core-needle   
biopsy at the Ewha Medical Center. Normal breast tissues were 
obtained from non-tumorous areas of breast cancer patients 
more than 10 cm from the primary cancer. All of the patients 
who were enrolled in this study gave written informed consent 
in accordance with the Declaration of Helsinki. The study was 
reviewed and approved by the local institutional review com-
mittees.  
Immunohistochemistry
The patterns of ANXA1 expression were examined by immu-
nohistochemical (IHC) staining. Breast tissues were formalin-
fixed and paraffin-embedded using standard methods. Mono-
clonal anti-ANXA1 antibody (catalog no. 610067; BD Trans-
duction Laboratories, Lexington, USA), a specific antibody for 
ANXA1, has been suitable for immunochemical use on a vari-
ety of formalin-fixed and paraffin-embedded tissues of bovine 
and human origin [10,11]. Monoclonal anti-ANXA antibody 
was added as a 100 mL aliquot at a concentration of 1 mg/mL. 
For isotype control monoclonal antibody (mAb), we used a 
purified mouse IgG1.kappa (MOPC 21) from Sigma Chemi-
cal (St. Louis, USA). Tissue sections were cut in 4 µm slices 
and mounted on protein-coated glass slides. After dewaxing in 
xylene and rehydration in a series of alcohols, the staining 
procedure was carried out as follows. All the linking and la-
beling reagents, substrates, and chromogens were supplied 
from BioGenex (San Ramon, USA) as a super-sensitive immu-
nodetection system. All procedures were carried out at room 
temperature. Before the mouse mAb was applied, a sufficient 
amount of protein blocking reagent (normal goat serum), which 
completely covered each tissue section, was placed on the slides 
for 20 minutes. After blotting around each section, primary 
mAb (1:100 dilution) was applied to the slides, incubated for 
60 minutes, followed by the addition of prediluted, biotinylated 
anti-immunoglobulin for 20 minutes, and a labeling agent     
(alkaline phosphatase-labeled streptavidin) for 20 minutes [12]. 
For the chromagen, one tablet of Fast Red substrate was dis-
solved in 5 mL of naphtol phosphate-substrate solution, and 
levamisole was added to the substrate solution to block endog-
enous alkaline phosphatase activity. Enough the chromogen 
substrate solution was added to cover each section entirely, and 
the slides were incubated for 10-30 minutes, or until acceptable 
color intensity developed. Finally, the slides were counterstained 
with Mayer’s hematoxylin solution and mounted with aqueous 
mounting medium (BioGenex). Each tissue section was anal-
ysed and scored by a pathologist. ANXA1 expression was scored 
as follows: the staining intensity was evaluated from 0 to 3 (rep-
resenting negative to strong staining, respectively) and % cells 
in each intensity was obtained. The overall score was determined 
as follows: overall score=[(% cells with visual score 1)×1]+[(% 
cells with visual score 2)×2]+[(% cells with visual score 3)×3]; 
expression was positive if the score was more than 70. The hor-
mone receptors (HR) (either., estrogen receptor or progester-
one receptor) were considered positive when ≥10% of positive 
Figure 1. Immunohistochemistry for Annexin A1 (ANXA1) expression. (A) ANXA1 is strongly expressed in myoepithelium (arrowhead) compared to 
epithelium (arrow) in normal breast tissue (×400). (B) There is a significant ANXA1 loss in invasive ductal carcinoma (×100).
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tumor cells had nuclear staining. Membranous staining for 
HER2 was scored as follows: 0, no staining or membranous 
staining in <10% of the cells; 1+, faint, incomplete staining in 
10% of the cells; 2+, weak-to-moderate complete staining in 
10% of the cells; and 3+, strong complete staining in 10% of 
the cells. HER2 overexpression was defined as a score of 3+. 
p53 was considered positive if >10% of the cells were stained 
with strong intensity.
Statistical analysis
Statistical analysis was performed with SPSS version 17.0 
(SPSS Inc., Chicago, USA). Pearson’s χ2 test was used to deter-
mine the correlation between variables, and the Cox propor-
tional regression hazard model was employed with several vari-
ables. Kaplan-Meier curves were plotted from breast cancer-
related survival (BCRS) and relapse-free survival (RFS) data. 
Univariate and multivariate p-values were two-sided and were 
considered to be significant when they were equal to or less 
than 0.05.  
 RESULTS
Cilinicopathologic characteristics of patients and 
immunohistochemical results of ANXA1
One hundred eighty-two cases were enrolled in this study, 
and the mean age of all female patients was 46.34±11.5 years. 
Table 1. Clinicopathologic characteristics related to Annexin A1 expression of 75 patients with invasive breast cancer
Variables No. %
ANXA1 negative ANXA1 positive
p-value
No. % No. %
Age (yr)* 50.11±12.52 47.81±10.45 0.458
Tumor size (cm) 1.000
   ≤2  30 41.5 22 73.3   8 26.7
   >2  44 58.5 31 70.5 13 29.5
Nodal status 1.000
   Negative  28 37.3 20 71.4   8 28.6
   Positive 47 62.7 34 72.3 13 27.9
Stage 0.180
   Early (stage 1-2B) 49 65.3 38 77.6 11 22.4
   Advanced (stage 3A-C) 26 34.7 16 61.5 10 38.5
Hormone receptor <0.001
   ER (+) and/or PR (+) 52 70.3 46 88.5   6 11.5
   ER (-) and PR (-)    22 27.7   7 31.8 15 68.2
HER2 overexpression 0.586
   No 50 67.6 37 74.0 13 26.0
   Yes 24 32.4 16 66.7   8 33.3
Intrinsic type <0.001
   Luminal A 36 49.3 32 88.9   4 11.1
   Luminal B 15 20.5 13 86.7   2 13.3
   HER2 8 11.0   2 25.0  6 75.0
   Triple negative 14 19.2   5 35.7   9 64.3
p53 expression 0.387
   Negative 20 28.6 16 80.0   4 20.0
   Positive 50 71.4 33 66.0 17 34.0
Nuclear grade 0.004
   I-II 48 69.6 40 83.3   8 16.7
   III 21 30.4 10 47.6 11 52.4
Histologic grade 0.347
   I-II 53 76.8 40 75.5 13 24.5
   III 16 23.2 10 62.5   6 27.5
Recurrence 0.084
   No 63 84.0 48 76.2 15 23.8
   Yes 12 16.0   6 50.0   6 50.0
Cancer-related death 0.091
   No 68 90.7 51 75.0 17 25.0
   Yes   7 9.3   3 42.9   4 57.1
ANXA1=Annexin A1; HR=hormone receptor; ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal growth factor receptor 2.
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ANXA1 was strongly expressed in myoepithelial cells com-
pared to epithelial cells in normal breast tissues (p<0.001) 
(Figure 1A). ANXA1 positivity was 87.7% in normal tissues, 
53.2% in benign diseases, 14.3% in DCIS, and 30.9% in inva-
sive carcinoma. A significant loss of ANXA1 expression was 
observed both in DCIS (n=7) and invasive carcinoma (n=75, 
Figure 1B) compared to normal epithelium (n=73, p<0.001) 
and benign breast diseases (n=27, p<0.001) including intra-
ductal papilloma (n=10), sclerosinng adenosis (n=4), atypical 
ductal hyperplasia (n=2), fibroadenoma (n=6), and fibrocys-
tic change (n=5). There was no difference between the ANXA1 
expression of DCIS and invasive carcinoma (p=1.000). In the 
analysis within invasive breast carcinoma, there was no signif-
icant difference in ANXA1 expression according to age (p= 
0.458), tumor size (p=1.000), nodal status (p=1.000), HER2 
overexpression (p=0.586), p53 expression (p=0.387), histologic 
grade (p=0.347), or recurrence (p=0.084). ANXA1 expres-
sion was significantly correlated with unfavorable prognostic 
factors including HR negativity (p<0.001), HER2 type and 
triple negative breast cancer (TNBC) (p<0.001), and high 
Table 2. Univariate Cox regression for breast cancer-related survival (BCRS) and relapse-free survival (RFS) in 75 patients with invasive breast cancer
Prognostic factors
BCRS RFS
RR 95% CI p-value RR 95% CI p-value
Age (yr)
   <50 vs. ≥ 50  0.329 0.040-2.734 0.303 0.960 0.289-3.188 0.947
Tumor size (cm)
   ≤2 vs. >2 0.491 0.110-2.197 0.352 0.656 0.212-2.035 0.466
Nodal status
   Negative vs. Positive 4.008 0.482-33.297 0.199 7.947 1.025-61.587 0.047
ANXA1 expression
   No vs. Yes 3.756 0.840-16.787 0.062 2.743 0.673-11.172 0.159
HR status
   ER (-) and PR (-) vs. ER (+) and/or PR (+) 0.096 0.063-1.255 0.076 0.172 0.052-0.573  0.004
HER2 overexpression
   No vs. Yes 5.517 1.068-28.512 0.022 4.680 1.408-15.550 0.012
Stage
   Early (I-IIB) vs. Advanced (IIIA-C) 5.077 0.984-26.183 0.031 11.766 2.572-53.815 0.001
p53 overexpression
   No vs. Yes 1.048 0.203-5.403 0.955 2.144 0.470-9.787 0.325
Nuclear grade
   I-II vs. III 1.765 0.395-7.888 0.451 5.186 1.559-17.249 0.007
Histologic grade
   I-II vs. III 1.436 0.278-7.408 0.664 2.552 0.809-8.048 0.097
RR=relative risk; CI=confidence interval; ANXA1=Annexin A1; HR=hormone receptor; ER=estrogen receptor; PR=progesterone receptor; HER2=human 
epidermal growth factor receptor 2.
Table 3. Multivariate analysis of prognosis factors for breast cancer-related survival (BCRS) and relapse-free survival (RFS) in patients with in invasive 
breast cancer (Cox’s proportional hazards model)
Prognostic factors
BCRS RFS
HR 95% CI p-value HR 95% CI p-value
ANXA1 expression
   No vs. Yes 2.251 0.332-15.266 0.406 1.297 0.299-5.618 0.728
Nuclear grade
   I-II vs. III 0.742 0.146-3.763 0.719 1.786 0.436-7.309 0.420
HR status
   ER (-) and PR (-) vs. ER (+) and/or PR (+) 0.683  0.089-5.227 0.713 0.480 0.085-2.701 0.405
HER2 overexpression
   No vs. Yes 3.829 0.683-21.460 0.127 3.704 1.081-12.698 0.037
Stage
   Early (I-IIB) vs. Advanced (IIIA-C) 2.758 0.423-18.006 0.289 5.211 1.015-26.740 0.048
HR=hazard ratio; CI=confidence interval; ANXA1=Annexin A1; HR=hormone receptor; ER=estrogen receptor; PR=progesterone receptor; HER2=human epi-
dermal growth factor receptor 2.266   Cha Kyong Yom, et al.
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nuclear grade (p=0.004) (Table 1). Althougth the data has not 
been shown in a table, there was no difference in ANXA1 ex-
pression among histologic subtypes of invasive breast cancer 
(p=0.520). 
Relationship between ANXA1 expression and clinical 
outcomes
The median follow-up duration was 63.0±24.08 months 
(range, 6.0-117.0) for invasive ductal carcinoma (n=75). In a 
univariate analysis, HER2 overexpression (p=0.022) and ad-
vanced stage (p=0.031) were correlated with poor BCRS (Table 
2). Although there was no statistical significance, ANXA1 ex-
pression tended to be associated with unfavorable BCRS (p= 
0.062). In relapse-free survival (RFS), nodal status (p=0.047), 
HR status (p=0.004), HER2 overexpression (p=0.012), TNM 
stage (p=0.001), and nuclear grade (p=0.007) had the statis-
tical significance. In contrast, there was no significant differ-
ence in BCRS and RFS according to ANXA1 expression in the 
multivariate analysis (Table 3). HER2 positivity and advanced 
stage were associated with poor RFS in multivariate analysis 
(p=0.037 and p=0.048, respectively).  
The ANXA1 positive group had significantly poor RFS in 
the node positive group (p=0.048, Figure 2A), in the HER2 
positive group (p=0.013, Figure 2B), and in the non-TNBC 
group (p=0.002, Figure 2C) compared to the ANXA1 negative 
group based in a Kaplan-Meier analysis (Table 4, Figure 2). 
DISCUSSION
A reduction in ANXA1 expression in breast cancer has been 
consistently reported [8,9], a finding which was corroborated 
by this study. We also identified that ANXA1 expression was 
more prominent in myoepithelium than in epithelium in nor-
mal breast tissue; however, disappearance of myoepithelial cells 
has been a major hallmark in invasive breast cancer [13]. Shen 
et al. [1] tried to determine whether the decreased integrated 
Table 4. Comparison of Kaplan-Meier analysis (log rank) for relapse-free survival (RFS) and Annexin A1 overexpression according to clinical variables
Clinical variables
ANXA1
p-value
Negative Positive Overall
Node-negative 0.136
   No. 20   9 29
   Recurrence   0   1   1
   Mean RFS
   95% CI
Node-positive 0.048
   No. 34 12 46
   Recurrence   6   5 11
   Mean RFS   98.96±6.69   56.62±12.56   91.47±6.70
   95% CI   85.86-112.07 32.01-81.23  78.32-104.61
HER2-negative 0.990
   No. 37 13 50
   Recurrence   3   1   4
   Mean RFS 100.42±4.21 87.33±6.38 100.35±3.67
   95% CI   92.17-108.66 74.82-99.84  93.16-107.55
HER2-positive 0.013
   No. 16   8 24
   Recurrence   3   5   8
   Mean RFS   98.75±9.56   33.13±11.29     82.25±10.09
   95% CI   80.01-117.49 10.98-55.26  62.47-102.03
Non-TNBC 0.002
   No. 48 12 60
   Recurrence   4   5   9
   Mean RFS 108.53±4.07   58.42±12.19 101.13±4.89
   95% CI 100.56-116.50 34.51-82.32  91.55-110.71
TNBC 0.269
   No. 5   9 14
   Recurrence 2   1   3
   Mean RFS     53.84±12.69 84.00±9.35   76.31±9.06
   95% CI 28.32-78.07   65.66-102.33 58.65-93.96
ANXA1=Annexin A1; CI=confidence interval; HER2=human epidermal growth factor receptor 2; TNBC=triple negative breast cancer.ANXA1 Expression in Breast Cancer 267
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maximal intensity of ANXA1 staining observed in DCIS sam-
ples was simply due to a reduction in the number of these cells, 
or if there was an underlying mechanism involved, such as a 
decreased level or frequency of cellular ANXA1 protein ex-
pression. They examined the expression of ANXA1 in myo-
epithelial cells from the TMA spots of normal, hyperplastic, and 
DCIS, and any minor expression was included. They concluded 
that the proportion of ANXA1 expression decreased, and the 
proportion of ANXA1 non-expressing areas increased in myo-
epithelial cells of non-malignant tissues compared to DCIS     
lesions. However, the distribution of ANXA1 expression in 
myoepithelial cells did not reveal notable differences between 
normal and hyperplastic ductal lesions. These results indicated 
that the loss of ANXA1 expression occurs early during malig-
nant transformation. In this study, we found a significant loss 
of ANXA1 expression both in DCIS and invasive carcinoma 
compared to normal epithelium and benign breast diseases 
which supports previous studies. There have been a number 
of theories about the potential mechanism of ANXA1 in can-
cer development. For example, ANXA1 has been linked with 
reduced cell proliferation involving the regulation of the extra-
cellular signal-regulated kinase (ERK)/mitogen-activated pro-
tein kinase (MAPK) signal transduction pathway. Forced ex-
pression of ANXA1 activates the ERK/MAPK pathway and 
reduces cell proliferation by disrupting the actin skeleton and 
ablating cyclin D1 expression [14,15]. Multiple members of 
the annexin family, including annexins 1, 2, 5, 6, and 7, have 
been reported to have involvement in the down-regulation of 
cell proliferation. Therefore ANXA1 has been postulated to 
have tumor suppressing properties [2,16]. 
On the contrary, some studies have shown that a higher level 
of ANXA1 in lymph node metastasis in comparison with pri-
mary breast cancer [14]. A similar finding was observed by 
Pencil and Toth [17] in rat metastatic mammary cancer and 
by Ahn et al. [18] in human breast cancer. Further, ANXA1 
expression was found to be down-regulated by breast cancer 
metastasis suppressor 1 gene in the MDA-MB-435 breast can-
cer cell line metastatic to the lung in an athymic mouse model 
[19]. A more recent study showed that membrane ANXA1 had 
an autocrine/paracrine action in stimulating the migration of 
SKCO-15 colorectal cancer cells through activation of n-formyl 
peptide receptors, which is a leukocyte migratory factor [20]. 
A recent study [21] showed that ANXA1 expression provoked 
drug resistance in breast cancer cells. The overexpression of 
ANXA1 induced resistance to anti-cancer drugs, and ANXA1-
depleted tumor cells showed increased sensitivity to anticancer 
drugs. Therefore, these results supported that ANXA1 also has 
oncogenic potential for breast cancer progression and metas-
tasis via multiple mechanisms. In the current study, ANXA1 
expression was significantly correlated with unfavorable prog-
nostic features of breast cancer, such as hormone receptor nega-
tivity (p<0.001), positive HER2 status and TNBC type (p< 
Figure 2. Five-year relapse-free survival according to Annexin A1 
(ANXA1) expression with clinical variables. ANXA1 positive groups have 
poor relapse-free survivals in node-positive patients (A), in HER2-posi-
tive patients (B), and in non-triple negative breast cancer patients (C).
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0.001), high nuclear grade (p=0.004). The ANXA1 positivity 
was also correlated with poor RFS in some groups of invasive 
breast cancer such as node positive, HER2 positive and non-
TNBC. This results could be explained that, in condition with 
unfavorable factors including node positive and HER2 positive 
status, ANXA1 might tend to re-express in cancer tissue and 
which result in more metastatic and aggressive phenotype. 
Given that this study had a limited number of patients, further 
study may be required to further support out findings. 
Although large scale, solid base studies are required to draw 
clinically meaningful conclusions, we found a major loss of 
ANXA1 in breast cancer tissues, including DCIS and invasive 
carcinoma, relative to normal and benign breast tissues. How-
ever, in cases of invasive breast cancer, ANXA1 positivity was 
significantly correlated with unfavorable prognostic factors. 
These results implied that ANXA1 plays dualistic roles and 
mechanisms in cancer development and progression in terms 
of both tumor suppressive and oncogenic activity. 
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